John Scarlett
Chief Executive Officer at GERON CORPORATION
Net worth: 445 000 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| V. Lawlis | M | 72 |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 18 years |
| Susan Molineaux | M | 70 |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | 19 years |
| Elaine Jones | M | 69 | 8 years | |
| Lloyd Rowland | M | 67 | 6 years | |
| Andrew Grethlein | M | 59 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 18 years |
| Chris Ogden | M | 40 | 3 years | |
| Alan Ashworth | M | 63 | 3 years | |
| Dawn Bir | F | 53 | 5 years | |
| Aron Feingold | M | - | 2 years | |
| Marcia Belvin | M | 57 | 6 years | |
| Elizabeth O'Farrell | F | 59 | 5 years | |
| Scott Samuels | M | 54 | - | |
| Robert Spiegel | M | 73 | 14 years | |
| Halley Gilbert | F | 54 | 4 years | |
| Michelle Robertson | F | 57 | 1 years | |
| Mani Mohindru | M | 52 | 4 years | |
| John McDonald | M | 63 | 2 years | |
| Gaurav Aggarwal | M | 51 | 1 years | |
| James Meyers | M | 59 | 6 years | |
| Shannon Odam | F | - | 5 years | |
| Melissa A. Kelly Behrs | F | 59 | 26 years | |
| Anil Kapur | M | 54 | 5 years | |
| Jeffrey Landau | M | 46 | 3 years | |
| Hong He | M | 55 | 4 years | |
| Edward E. Koval | M | 62 | 3 years | |
| Ethel M. Koczon | F | - | 9 years | |
| Faye Feller | M | 42 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Greenwood | M | 72 | 16 years | |
| Olivia Bloom | F | 55 | 29 years | |
| Ho Young Huh | M | 54 | 8 years | |
| Roni Mamluk | M | 57 | 15 years | |
| Stephen N. Rosenfield | M | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 5 years |
| Debanjan Ray | M | 46 | 8 years | |
| Alexander E. Barkas | M | 76 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 19 years |
| Mark J. Fitzpatrick | M | 61 | 6 years | |
| Richard Hawkins | M | 75 |
Sensus Drug Development Corp.
 Sensus Drug Development Corp. Pharmaceuticals: OtherHealth Technology Part of Pfizer Inc., Sensus Drug Development Corp. is a company that develops drugs to treat endocrine disorders. The company is based in San Antonio, TX. The company was founded by John A. Scarlett, Richard J. Hawkins. Sensus Drug Development was acquired by Pharmacia Corp. on March 07, 2001.
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 8 years |
| Mark Leuchtenberger | M | 67 | 1 years | |
| Rajkumar Kannan | M | 61 | 2 years | |
| Karin Eastham | F | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 20 years |
| David J. Earp | M | 59 | 13 years | |
| Amy Peterson | M | 57 | 3 years | |
| Drew Enamait | M | 50 | 6 years | |
| Timothy Shannon | M | 65 | 5 years | |
| John Doyle | M | 46 | - | |
| Chaime Orlev | M | 53 | 6 years | |
| Neil Exter | M | 65 | 7 years | |
| Jason Fredette | M | - | 1 years | |
| Chau Cheng | M | - | 2 years | |
| lee Giguere | M | 43 | 2 years | |
| Robin Knifsend | F | 55 | - | |
| Howard Moore | M | - |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | - |
| Charles S. Fuchs | M | 63 | - | |
| Rachel Humphrey | M | 62 | 4 years | |
| Scott Minick | M | 72 | 14 years | |
| Anand Varadan | M | 57 | 3 years | |
| Tara Mccarthy | F | 50 | - | |
| Marion McCourt | F | 64 | 1 years | |
| Dawn Schottlandt | F | - | 1 years | |
| Dror Brandwein | M | - | 3 years | |
| Philip D. Reilly | M | - | - | |
| Ross G. Clark | M | 73 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 7 years |
| Thomas Hofstaetter | M | 75 | 5 years | |
| James Tobin | M | 79 | 1 years | |
| Edward V. Fritzky | M | 73 | 15 years | |
| John Thero | M | 63 | 6 years | |
| Ansbert Gadicke | M | 66 | 2 years | |
| Thomas D. Kiley | M | 80 | 21 years | |
| David Stack | M | 72 | 7 years | |
| Vincent J. Miles | M | 73 | 3 years | |
| Craig Parker | M | 63 | 2 years | |
| David Plante | M | - | 3 years | |
| Thorsten von Stein | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 9 years |
| Nick Galli | M | - | 2 years | |
| Alison Hannah | M | 63 | 2 years | |
| Ajay Bansal | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 2 years |
| Carlos Campoy | M | 60 | 2 years | |
| Christopher Rivera | M | 63 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
| Faheem Hasnain | M | 65 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | - |
| Christophe Jean | M | 67 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 2 years |
| Richard B. Love | M | 62 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 4 years |
| Ralph Brandenberger | M | 55 | 11 years | |
| Dennis J. Henner | M | 72 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 6 years |
| Mark Leschly | M | 55 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 5 years |
| Robert Goeltz | M | 51 | 2 years | |
| Gordon Treadway | M | - |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 7 years |
| David Mahoney | M | 69 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 4 years |
| Thomas Wiggans | M | 72 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
| William Michael Kavanaugh | M | 67 | 5 years | |
| Cynthia J. Ladd | F | 68 | 3 years | |
| Michael Astrue | M | 67 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
| Thomas H. Silberg | M | 76 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
| Timothy Patrick Lynch | M | 54 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 3 years |
| Asi Haviv | M | - | 9 years | |
| Melanie I. Nallicheri | F | 56 | 2 years | |
| Edward D. Wirth | M | 59 | 7 years | |
| Jean-Luc Bélingard | M | 74 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | 1 years |
| Sergei Gryaznov | M | 64 | 15 years | |
| Kirk Trisler | M | 64 | 3 years | |
| Avanish Vellanki | M | 49 |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | - |
| Xiao Lin Wang | M | 53 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Scarlett
- Personal Network
